BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
IPO Year:
Exchange: NASDAQ
Website: bdsi.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2022 | $5.00 → $5.60 | Overweight → Neutral | Piper Sandler |
| 1/21/2022 | $4.00 → $4.50 | Neutral | HC Wainwright & Co. |
| 11/4/2021 | $6.00 → $4.50 | Buy → Neutral | HC Wainwright & Co. |
| 8/5/2021 | $5.50 → $6.00 | Buy | HC Wainwright & Co. |
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)
Piper Sandler downgraded BioDelivery Sciences Intl from Overweight to Neutral and set a new price target of $5.60 from $5.00 previously
HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Neutral and set a new price target of $4.50 from $4.00 previously
HC Wainwright & Co. downgraded BioDelivery Sciences Intl from Buy to Neutral and set a new price target of $4.50 from $6.00 previously
HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Buy and set a new price target of $6.00 from $5.50 previously
HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Buy and set a new price target of $5.50 from $7.00 previously
15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
POS AM - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
8-K - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
SC 14D9/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
SC 14D9/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
10-K - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)
SC 14D9/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
SC 14D9 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)
RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021. Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults. "ELYXYB represents a significant innovation in
- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology - - Conference Call Scheduled for Today at 8:30 a.m. ET - STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that addre
Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock's closing price of $3.64 on February 11, 2022 and a 65% premium to the 30 trading days volume weighted average price of $3.40 Transaction expected to close late in the first quarter of 2022 RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it has entered into a definitive merger agreement for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to purchase all outstanding share
Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million 2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million RALEIGH, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced it expects 2021 total Company net revenues and BELBUCA® (buprenorphine buccal film) net sales to a
RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. District Court of Delaware has issued an opinion in favor of BDSI in the company's patent litigation against Alvogen Group, Inc. and its affiliates, who filed an Abbreviated New Drug Application (ANDA) for BDSI's BELBUCA® product on May 23, 2018. The opinion by the trial judge upholds the validity of claims in BDSI's patents 8,147,866 (the ‘866 patent), which expires in 2027, and 9,901,539 (the ‘539 patent), which expires in 2032. Alvogen con
Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended
RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021. Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h